{
    "nctId": "NCT04143906",
    "briefTitle": "Vinorelbine/Carboplatin Versus Gemcitabine/Carboplatin in Metastatic Breast Cancer",
    "officialTitle": "Randomised, Multicenter Phase II Study in Patients With Metastatic Breast Cancer With Vinorelbine Plus Carboplatin Versus Gemcitabine Plus Carboplatin",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 200,
    "primaryOutcomeMeasure": "Progression Free Survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Histologically confirmed metastatic breast cancer;\n2. All patients were required to give written informed consent;\n3. To have received a previous treatment with anthracyclines and taxanes;\n4. Previous radiotherapy is allowed, whenever the radiated area is not the only disease location;\n5. At least 4 weeks since the last previous antineoplastic treatment;\n6. Patients must have recovered from all previous toxicities;\n7. Karnofsky Performance status \\>= 70%;\n8. Adequate hematological, renal, cardiac and hepatic function;\n9. Life expectancy of at least 12 weeks;\n10. Patients able to comply and to receive an adequate follow-up;\n\nExclusion Criteria:\n\n1. Only bone metastases;\n2. Active infection;\n3. Previous treatment with one of the study drugs;\n4. Application of other cytotoxic chemotherapy;\n5. Insufficient renal function (creatinine clearance \\< 60ml/min);\n6. Clinically unstable brain metastasis;\n7. Pregnancy or lactation;\n8. Other primary malignancies (other than carcinoma-in-situ of the cervix or adequately treated basal cell cancer of the skin);\n9. Abnormal liver function (bilirubin \\> 2.0-fold upper normal limit (UNL); Alanine aminotransferase and aspartate aminotransferase \\>2.5-fold UNL). In patients with hepatic metastasis, a value of Alanine aminotransferase and aspartate aminotransferase of up to 5-fold UNL is permitted;\n10. Males;\n11. Second malignancy (except for cervix carcinoma in situ or skin carcinoma - no melanoma- with an adequate treatment). Previous malignancies are allowed if disease-free survival is superior to 5 years, except for renal carcinoma or melanoma;",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}